KanryAb™ Humanized Anti-Human IFN-γ mAb (Det)

Application Scenarios & Buyer Advantages Scenario: IVD Biomarker Kit Manufacturers Local Pain Point: Low assay signal and unstable signal-to-noise ratio caused by poorly matched detection clones, extending assay optimization cycles. Product Advantage: Pre-validated to match our IFN-gamma capture antibody; delivers high signal-to-noise ratio, keeps assay CV below 7.8%, cuts assay optimization time by 41%, stable performance across multiple batches.   Scenario: CRO Bioanalysis Laboratories Local Pain Point: Batch variation of detection antibody compromises assay reproducibility of drug quantitation and biomarker testing. Product Advantage: Rigorous batch release testing with complete documentation; lot-to-lot signal variation ≤5%, fully meets GLP requirements for bioanalytical method validation.   Scenario: Biotech R&D Institutes & Academic Labs Local Pain Point: Long lead time and high cost to source qualified humanized detection antibodies from overseas vendors. Product Adv…